belimumab

01/01/2021 - "Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme."
07/01/2020 - "Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study."
01/01/2018 - "In patients with moderate-to-severe systemic lupus erythematosus, subcutaneous belimumab 200 mg once weekly plus standard of care significantly improved the systemic lupus erythematosus responder index. "
01/01/2018 - "BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus."
01/01/2021 - "Belimumab is both safe and effective for the treatment of systemic lupus erythematosus. "

01/01/2018 - "Eligible patients with biopsy-proven LN (revised American College of Rheumatology or Systemic Lupus Collaborating Clinics criteria) were identified and categorized into ordinal (CR, PR, or no remission) or binary (response or no response) renal remission categories at 24 months post-diagnosis [modified Aspreva Lupus Management Study (mALMS) and modified Belimumab International Lupus Nephritis Study (mBLISS-LN) criteria]. "
01/01/2021 - "Efficacy of belimumab monotherapy in high infectious risk patient affected by lupus nephritis."
01/28/2023 - "Belimumab may be effective and safe in lupus nephritis even with regard to hematologic complications."
11/01/2022 - "In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. "
11/01/2022 - "Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study."

01/01/2023 - "In our case-control study, significant improvement in proteinuria was demonstrated with belimumab at Week 48 (p = 0.037) and at all subsequent time points (all p < 0.05). "
01/01/2017 - "In support of the latter hypothesis is the quick resolution/significant reduction of proteinuria shortly after belimumab discontinuation and before other treatment measures had any reasonable effect. "
04/01/2022 - "In an exposure response analysis, the efficacy of belimumab as evaluated by renal response was mainly driven by patients with lower proteinuria at baseline regardless of other baseline characteristics (e.g. "
12/01/2013 - "Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. "
01/01/2020 - "In this prospective, open-label, experimental medicine study, 14 participants with PMN and persistent nephrotic-range proteinuria received up to 2 years belimumab monotherapy (10 mg/kg, every 4 weeks). "

05/01/2014 - "In pooled analysis, significantly greater improvements in PCS, SF-36 vitality domain, and FACIT-Fatigue scores at week 52 were evident with both belimumab doses. "
01/01/2021 - "While no impact was documented for disease activity, established organ damage contributed to adverse outcome within physical HRQoL aspects and add-on belimumab was shown to be protective against adverse physical functioning and severe fatigue."
01/01/2023 - "Belimumab has been shown to induce clinically important improvements in physical aspects of HRQoL and in fatigue, the latter being a common and major complaint within the SLE population. "
01/01/2021 - "A protective effect of belimumab against adverse general health and severe fatigue was implicated."
01/01/2020 - "Belimumab ist eine inzwischen gut etablierte Add-on-Therapie in erster Linie zur Behandlung des Gelenk- und Hautbefalls sowie der Fatigue. "

01/01/2019 - "Compared with placebo, treatment with belimumab did not reduce the risk of a PSE (adjusted hazard ratio [HR] 1.07, 95% confidence interval [95% CI] 0.44-2.59; P = 0.884) or vasculitis relapse (adjusted HR 0.88, 95% CI 0.29-2.65; P = 0.821). "
01/01/2023 - "Treatment-resistant systemic lupus erythematosus-associated hypocomplementic urticarial vasculitis successfully treated with belimumab."
01/01/2022 - "Treatment of refractory hypocomplementaemic urticarial vasculitis syndrome progressing to systemic lupus erythematosus with belimumab."
01/01/2019 - "All vasculitis relapses in the belimumab group (n = 6) occurred in patients who had PR3-ANCA-associated vasculitis with cyclophosphamide-induced disease remission. "
11/01/2021 - "Type II cryoglobulinaemic vasculitis with primary Sjögren's syndrome successfully treated with belimumab and hydroxychloroquine."